Table 1.
Summary of characteristics of included studies in the systematic review, excluding case series/reports (N = 31).
| Type of SUD assessed (N) studies | |
| Cannabis | 6 |
| Alcohol | 5 |
| Opioids | — |
| Cocaine | 2 |
| Methamphetamine | 1 |
| Poly-drug use | 16 |
| Not specified | 1 |
| Study design (N) studies | |
| Case reports/series | 13 |
| Phase 1 | 1 |
| Pharmacovigilance case analysis | 1 |
| Retrospective observational cohort | 6 |
| Prospective observational cohort | 5 |
| RCT | 3 |
| National Survey Study | 1 |
| Observational registry-based study | 1 |
| Antipsychotic comparison to clozapine excluding case reports and series, (N) studies | |
| FGA only | 3 |
| Second-generation antipsychotic (SGA) only | 5 |
| FGA + SGA | 8 |
| Outcome reported (N) studies | |
| Abstinence | 15 |
| Reduction in use | 10 |
| Reduction in craving | 3 |
| Reduction in psychiatric hospitalization | 3 |
| Odds of developing SUD | 1 |
| Country of origin of the studies | |
| USA | 15 |
| Europe | 11 |
| Canada | 1 |
| Australia | 1 |
| Malaysia | 1 |
| Iran | 1 |
| S. Korea | 1 |